SGLT2i & Erythrocytosis | Medscape 2026
SGLT2i & Erythrocytosis | Medscape 2026
• SGLT2 inhibitors can ↑ Hb/Hct.
• SGLT2i increased erythrocytosis prevalence by ~6%; meta-analysis: Hct +2.27%, Hb +0.62 g/dL vs placebo.
• Effect likely reflects ↑ erythropoiesis, not simply diuresis.
• Empagliflozin may have a greater effect than dapagliflozin.
• Clinical pearl: Consider SGLT2i as a reversible cause of unexplained erythrocytosis.
Source: Medscape | Sep 11, 2026.